Table 1

Contemporary multi-institutional reports—HD IL-2 outcome

ReportResponseSurvival
Clark et al 4
RCC (2011–2015), sequenced with targeted therapy
N=352 (328 with response data)
PROCLAIM registry database
CR 4%, PR 13%, SD 39%, PD 43%
CR+PR+SD 53%
Median OS—NR for CR, PR, SD
Median OS—PD—15.5 months
PD followed by TT—med OS 29.7 months; PD no TT—med OS 8.5 months
2.5-year OS—CR 100%; PR 75%, SD 78%, PD 39%
McDermott et al 5
RCC n=120
Multi-institution, prospective trial
ORR 25%, CR 3, PR 27
13 (11%) progression-free at 3 years
Median OS 42.8 months
80% TT after IL-2
Alva et al 6
mM (2005–2012)—n=170
RCC (2005–2012)—n=192
Survival current 2015
PROCLAIM registry database
mM: CR 5% PR 10% SD 22%
CR+PR+SD 58% median f/u 43.1 months
RCC: CR 6%, PR 9%, SD 22%
CR+PR+SD 70% median f/u 46.6 months
Median OS 19.6 months
Median OS—NR for CR, PR
Median OS 33.4 months—SD
Median OS 41 months
Median OS—NR for CR, PR
Median OS 49.6 months—SD
Stenehjem et al 7
RCC n=391
U Utah 1988–2013
U Mich 1997–2013
CR 9% PR 10%, SD 32% PD 42%
CR+PR+SD 51%
Median OS CR—13+ years
Median OS PR—37.8 months
Median OS SD—34.4 months
  • CR, complete response; f/u, follow-up; IL, interleukin; mM, metastatic melanoma; N, number; NR, not reached; ORR, overall response rate; OS, overall survival; PD, progressive disease; PR, partial response; RCC, renal cell carcinoma; SD, stable disease; TT, targeted therapy; U, university.